Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce★★★★★4.8/5 on G2
Nusano Announces Series C Financing of Over $115M with The Wasatch Group and S32
Oct 01, 2024
Contract Type
partnership
West Valley CityManufacturingInformation TechnologyBiotechnologyHealth CareMedicalMedical Deviceresearch
Description
Nusano, Inc. announced a Series C financing round with funding commitments of over $115 million led by The Wasatch Group, with additional participation by S32. The financing will support the company’s initial product launches of non-carrier-added lutetium-177 (n.c.a. Lu-177) and actinium-225 (Ac-225).
Quick answer
Nusano Announces Series C Financing of Over $115M with The Wasatch Group and S32 (October 1, 2024). Nusano is based in West Valley City, Utah, United States.
What agreement did Nusano announce on October 1, 2024?
Nusano, Inc. announced a Series C financing round with funding commitments of over $115 million led by The Wasatch Group, with additional participation by S32. The financing will support the company’s initial product launches of non-carrier-added lutetium-177 (n.c.a.
What does Nusano do?
Nusano is a medical technology company that creates radioisotopes—tiny tracers used by doctors to diagnose and treat cancer and other diseases.
Where is Nusano based?
Nusano is based in West Valley City, Utah, United States.
Source: Fundz verified event record.
Company Information
Company
Nusano
Location
4669 W Lake Park Blvd
West Valley City, Utah, United States
About
Nusano is a medical technology company that creates radioisotopes—tiny tracers used by doctors to diagnose and treat cancer and other diseases. Doctors use these tiny tracers like flashlights to light up areas inside the body. They can see how blood is flowing, how organs are functioning, even how cells are growing. Advanced medicines and treatment methods also use radioisotopes to target and eliminate cancer cells with precision.